Ongoing Challenges in Pharmacovigilance Gerald J. Dal Pan Current Opinion 22 November 2013 Pages: 1 - 8
EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars Begoña CalvoLeyre Zuñiga Leading Article 05 November 2013 Pages: 9 - 18
Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis Ursula ReichenpfaderGerald GartlehnerBradley N. Gaynes Systematic Review 13 December 2013 Pages: 19 - 31
Post-Approval Evaluation of Effectiveness of Risk Minimisation: Methods, Challenges and Interpretation Anjan Kumar BanerjeeInge M. ZomerdijkStephen J. Mayall Review Article 20 December 2013 Pages: 33 - 42
Anti-Tuberculosis Drug-Induced Liver Injury in Shanghai: Validation of Hy’s Law Xin ShenZheng’an YuanFan Wu Original Research Article 08 November 2013 Pages: 43 - 51
Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia Izyan A.WahabNicole L. PrattElizabeth E. Roughead Original Research Article 16 November 2013 Pages: 53 - 64
vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues Tomas BergvallG. Niklas NorénMarie Lindquist Original Research Article Open access 17 December 2013 Pages: 65 - 77